Volume 5, Number 6—December 1999
The First Reported Case of Aerococcus Bacteremia in a Patient with HIV Infection
To the Editor: We report the first case of Aerococcus viridans bacteremia in a patient with HIV infection. Two species in the genus Aerococcus have been implicated as rare pathogens in humans. A. urinae causes urinary tract infections; the other species, A. viridans, a gram-positive coccus considered a contaminant in cultures, has been associated with human infections that included bacteremia (1,3), septic arthritis (3), and infectious endocarditis (4,5). Widely distributed in the environment, the organism has been recovered from dust, vegetables, and crustaceans (6) and was isolated from different areas in a hospital (recovery room, intensive care unit, delivery room, treatment room, premature nursery) and from numerous objects (7).
We describe the first case of A. viridans bacteremia in a patient with HIV. A 34-year-old man without notable medical history sought medical attention after several weeks of epigastric midabdominal pain associated with a 15-lb weight loss; the pain did not respond to antacid medications. The patient said that he did not have fever, chills, night sweats, or history of transfusions and did not use alcohol, tobacco, or drugs. He had engaged in homosexual activity 2 to 3 years earlier.
Physical examination showed moderate cachexia and low-grade fever (38.8ºC) associated with tachycardia, but the heart and lung examination was otherwise normal. The abdomen was soft, flat, and tender to palpation in the midabdominal epigastric area, without hepatosplenomegaly, guarding, or rebound tenderness. No other abnormalities were identified. The patient was admitted to the hospital, and the initial set of routine blood cultures (Bactec 9240 instrument, Becton Dickinson, Sparks, MD) showed no growth. On hospital day 2, he began to have severe rigors, along with persistent fever. A second set of blood cultures drawn at that time grew paired gram-positive cocci in less than 24 hours. The patient was empirically started on penicillin G, and cefotaxime was added shortly thereafter because of the possibility of intermediately resistant pneumococcus. The rigors responded to antibiotic treatment, and a third set of blood cultures showed no growth. The negative blood cultures before and after appropriate antimicrobial therapy and the short time to detection (which suggests a large initial inoculum) led us to believe that the organism in this case was a true pathogen and not a contaminant.
The patient's work-up included a normal abdominal computer tomography; abdominal ultrasound showed nonobstructing cholelithiasis. Laboratory tests demonstrated anemia of chronic disease diagnosed by a hematocrit of 25% associated with a low reticulocyte production index, high serum ferritin, and an elevated erythrocyte sedimentation rate (91 mm/hr), with polyclonal hypergammaglobulinemia and hypoalbuminemia on serum protein electrophoresis. Stool samples were negative for occult blood, and serologic tests showed no Helicobacter pylori antibodies. The patient's total lymphocyte count was 300 cells/µl, HIV serologic testing by enzyme-linked immunosorbent assay and Western blot was positive, and flow cytometry revealed an absolute CD4+ T-lymphocyte count of 19 cells/µl, with an HIV-1 retroviral titer of 280,000 by polymerase chain reaction. Gallium scanning was negative for Pneumocystis carinii pneumonia and gastrointestinal lymphoma. A follow-up endoscopy showed esophageal ulcers, with disruption of the mucosal barrier. Blood cultures were negative for cytomegalovirus or mycobacteria, but the aerobic isolate initially reported as paired gram-positive cocci was later identified as A. viridans.
The identification of A. viridans was made on the basis of the following characteristics: catalase negativity, a-hemolytic gram-positive cocci forming pairs and tetrads (not chains) in broth culture; growth in the presence of 40% bile and 6.5% NaCl and ability to hydrolyze esculin; pyrrolidony l-aminopeptidase positivity, leucine-aminopeptidase negativity; and production of acid from trehalose, sucrose, maltose, and lactose but not from sorbitol.
Susceptibility testing by the agar dilution method showed that the isolate was susceptible to penicillin-G (MIC = 0.12 µg/ml) and vancomycin (MIC = 0.25 µg/ml). On the basis of this case and previous reports (1,2), we believe that A. viridans is a potential pathogen that can cause serious infections in immunocompromised patients. The presumed route of infection in this patient was esophageal ulcers. Clinical microbiologists should pay close attention to a-hemolytic, catalase-negative streptococci recovered from sterile body sites that form tetrads rather than chains on Gram stain.
- Swanson H, Cutts E, Lepow M. Penicillin-resistant Aerococcus viridans bacteremia in a child receiving prophylaxis for sickle-cell disease. Clin Infect Dis. 1996;22:387–8.
- Kern W, Vanek E. Aerococcus bacteremia associated with granulocytopenia. Eur J Clin Microbiol. 1987;6:670–3.
- Taylor PW, Trueblood MC. Septic arthritis due to Aerococcus viridans. J Rheumatol. 1985;5:1004–5.
- Untereker WJ, Hanna BA. Endocarditis and osteomyelitis caused by Aerococcus viridans. Mt Sinai J Med. 1976;43:248–52.
- Janosek J, Eckert J, Hudac A. Aerococcus viridans as a causative agent of infectious endocardititis. J Hyg Epidemiol Microbiol Immunol. 1980;1:92–6.
- Pien FD, Wilson WR, Kunz K, Washington JA II. Aerococcus viridans endocarditis. Mayo Clin Proc. 1984;59:47–8.
- Kerbaugh MA, Evans JB. Aerococcus viridans in the hospital environment. Appl Microbiol. 1968;16:519–23.
Suggested citation: Razeq JH, Thomas GM, Alexander D. The First Reported Case of Aerococcus Bacteremia in a Patient with HIV Infection [letter]. Emerg Infect Dis [serial on the Internet]. 1999, Dec [date cited]. Available from http://wwwnc.cdc.gov/eid/article/5/6/99-0622 First Reported Case of Aerococcus Bacteremia in a Patient with HIV Infection
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 16, 2010
- Page last updated: December 16, 2010
- Page last reviewed: December 16, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)